Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Technology appraisal guidance
Reference number: TA607
Published:
Publication of the final guidance is on hold while questions around the budget impact are resolved. An expected publication date will be added to this page when it is confirmed.